FDA Approves Humira Biosimilar Hyrimoz for Treatment of IBD, Other Conditions

FDA Approves Humira Biosimilar Hyrimoz for Treatment of IBD, Other Conditions
The U.S. Food and Drug Administration (FDA) approved Hyrimoz (adalimumab-adaz, by Sandoz), a biosimilar to AbbVie’s Humira (adalimumab) for the treatment of Crohn’s disease (CD) in adults and ulcerative colitis (UC). A biosimilar is a therapeutic that has similar active properties to an original product. “Biosimilars can help people suffering from chronic, debilitating conditions gain expanded access to

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *